Clinical Trials on Mesothelioma in New Zealand

Total 116 results

Morphotek

Completed

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma (Amatuximab)

Malignant Pleural Mesothelioma

United States, Canada, Germany, Spain, Netherlands
Morphotek

Terminated

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) (ARTEMIS)

Mesothelioma, Malignant

France, United Kingdom, United States, Germany, Australia, Italy
Wake Forest University
Johns Hopkins University; Memorial Sloan Kettering Cancer Center; Mayo Clinic; University... and other collaborators

Completed

Do Your Genes Put You at a Higher Risk of Developing Mesothelioma

Mesothelioma

United States
Eli Lilly and Company

Approved for marketing

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Mesothelioma

United States, Brazil, Egypt, Saudi Arabia
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Innovive Pharmaceuticals

Completed

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Myelodysplastic Syndromes | Leukemia | Lung Cancer | Malignant Mesothelioma | Primary Peritoneal Cavity Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Malignant Mesothelioma

United States
AGC Biologics S.p.A.

Completed

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Malignant Pleural Mesothelioma

United States, Spain, United Kingdom, Ireland, Italy, Belgium, Egypt, Canada, France, Netherlands, Poland, Sweden
AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

Denmark, Italy, Australia, Korea, Republic of, Belgium, Poland, United States, Canada, Japan, United Kingdom, Spain, China, France, Taiwan, Norway, Brazil, Germany, Switzerland, South Africa, Turkey, Netherlands
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Mesothelioma | Wilms Tumor | Pleural Mesothelioma

United States
Ikena Oncology

Active, not recruiting

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Solid Tumor | Solid Tumors, Adult | Malignant Pleural Mesothelioma (MPM) | Epithelioid Hemangioendothelioma (EHE) | NF2 Deficient Mesothelioma | Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes | NF2 Deficiency | YAP1 or TAZ Gene Fusions

United States, United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

Malignant Mesothelioma

United States
Eli Lilly and Company

Completed

A Study of LY3023414 in Participants With Advanced Cancer

Non-Hodgkin's Lymphoma | Metastatic Cancer | Malignant Mesothelioma | Metastatic Breast Cancer | Non-small Cell Lung Cancer | Advanced Cancer

United States, Puerto Rico, Italy
Epizyme, Inc.

Completed

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Mesothelioma | BAP1 Loss of Function

United States, United Kingdom, France
MaxCyte, Inc.
CTI Clinical Trial and Consulting Services

Terminated

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Fallopian Tube Adenocarcinoma | Peritoneal Mesothelioma | Primary Peritoneal Carcinoma | Adenocarcinoma of the Ovary

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Alanosine in Treating Patients With Cancer

Sarcoma | Pancreatic Cancer | Lung Cancer | Malignant Mesothelioma

United States
Polaris Group

Completed

Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC)

Mesothelioma

United States, United Kingdom, Taiwan, Australia, Italy
Bayer
ImmunoGen and MorphoSys

Completed

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Mesothelioma

Belgium, France, United States, Canada, Spain, Turkey, United Kingdom, Australia, Finland, Italy, Poland, Korea, Republic of, Netherlands, Russian Federation
Checkpoint Therapeutics, Inc.
Novotech (Australia) Pty Limited

Recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Non Hodgkin Lymphoma | Endometrial Cancer | Carcinoma, Small Cell | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Malignant Mesothelioma, Advanced

Australia, New Zealand, Thailand, Ukraine, Spain, Russian Federation, France, Poland, South Africa
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)

Mesothelioma

Brazil, United States, China, Italy, Australia, Belgium, Chile, Colombia, France, Germany, Greece, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, South Africa, Switzerland, Turkey, United Kingdom
TCR2 Therapeutics

Active, not recruiting

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Colorectal Neoplasms | Colorectal Cancer | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Cholangiocarcinoma | Triple Negative Breast Cancer | Ovarian Adenocarcinoma | Mesotheliomas Pleural and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); North Central Cancer Treatment Group

Completed

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Mesothelioma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

Depression | Small Cell Lung Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Malignant Mesothelioma | Non-small Cell Lung Cancer | Liver Cancer | Anxiety Disorder | Extrahepatic Bile Duct Cancer

United States
Boehringer Ingelheim

Terminated

Nintedanib (BIBF 1120) in Mesothelioma

Mesothelioma

United States, Spain, Canada, United Kingdom, Belgium, Czechia, Sweden, Australia, Germany, Italy, Japan, Russian Federation, Israel, Poland, France, Netherlands, Austria, Mexico, Portugal, Egypt, Argentina, Croatia, Chile, Denmark, Norway and more
Memorial Sloan Kettering Cancer Center
United States Department of Defense; Bellicum Pharmaceuticals

Active, not recruiting

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Breast Cancer | Lung Cancer | Mesothelioma | Metastases | Malignant Pleural Disease

United States
Albert Einstein College of Medicine

Completed

Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C

Gastric Cancer | Colorectal Cancer | Pseudomyxoma Peritonei | Peritoneal Carcinomatosis | Peritoneal Mesothelioma | Appendiceal Cancer

United States
Aminex Therapeutics, Inc.

Recruiting

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Melanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditions

United States, Australia
Inhibrx, Inc.

Recruiting

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Sarcoma | Pancreatic Adenocarcinoma | Ewing Sarcoma | Gastric Adenocarcinoma | Chondrosarcoma | Solid Tumors | Malignant Pleural Mesothelioma | Colorectal Adenocarcinoma | GIST | SDH-deficient Solid Tumors

United States
Prelude Therapeutics

Active, not recruiting

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Sarcoma | Breast Cancer | Glioblastoma | Malignant Mesothelioma | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Non-small Cell Lung Cancers

United States, Singapore
Eli Lilly and Company

Completed

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

Pleural Neoplasms

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (BASECAMP-1)

Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Pancreas Cancer | Ovarian Carcinoma | Solid Tumor, Adult | CRC | Mesothelioma; Lung

United States
Memorial Sloan Kettering Cancer Center
Genelux Corporation

Active, not recruiting

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Lung Cancer

United States
Stony Brook University
University of Iowa; Ipsen; Barbara Ann Karmanos Cancer Institute

Completed

Phase I Trial HIPEC With Nal-irinotecan

Gastric Cancer | Colorectal Cancer | Mesothelioma | Pseudomyxoma Peritonei | Peritoneal Cancer | Mucinous Adenocarcinoma | Primary Peritoneal Carcinoma | Mucinous Tumor

United States
Vivace Therapeutics, Inc

Recruiting

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 or mNF2 Gene Mutations

Mesothelioma | Solid Tumor, Adult

United States, Australia
Infinity Pharmaceuticals, Inc.

Active, not recruiting

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Advanced Solid Tumors (Part A/B/C/D) | Non-small Cell Lung Cancer (Part E) | Melanoma (Part E) | Squamous Cell Cancer of the Head and Neck (Part E) | Triple Negative Breast Cancer (Part F) | Adrenocortical Carcinoma (Part G) | Mesothelioma (Part G) | High-circulating Myeloid-derived Suppressor Cells...

United States
7 Hills Pharma, LLC

Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Melanoma | Kidney Cancer | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Non Small Cell Lung Cancer | Skin Cancer | Metastasis | Advanced Solid Tumor | Advanced Cancer | Renal Cell Cancer | Hepatocellular Cancer | Mismatch Repair Deficiency | Pleural Mesothelioma | MSI-High | Anaplastic Lymphoma... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Triple-Negative Breast Carcinoma and other conditions

United States, Canada
Mirati Therapeutics Inc.

Recruiting

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Pancreatic Adenocarcinoma | Solid Tumor | Non Small Cell Lung Cancer | Mesothelioma | Advanced Solid Tumor | Malignant Peripheral Nerve Sheath Tumors

United States
Quadriga Biosciences, Inc.
Novotech (Australia) Pty Limited

Completed

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Melanoma | Sarcoma | Kidney Cancer | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Astrocytoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Thymic Carcinoma | Lung Cancer | Prostate Cancer | Brain Cancer | Cholangiocarcinoma | Bladder Cancer | Liver Cancer | Brain Metastases | Tongue Cancer | Esophagus... and other conditions

Australia
Compass Therapeutics
Iqvia Pty Ltd; Merck, Sharp & Dohme, LLC, Rahway, NJ USA

Recruiting

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Melanoma | Head and Neck Cancer | Small Cell Lung Cancer | Metastatic Cancer | Mesothelioma | Non-small Cell Lung Cancer | Locally Advanced Solid Tumor

United States
Multitude Therapeutics Inc.
Tigermed Consulting Co., Ltd

Recruiting

AMT-151 in Patients With Selected Advanced Solid Tumours

Ovarian Cancer | Ovarian Epithelial Cancer | Lung Adenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Endometrial Cancer | Advanced Cancer | Ovarian Clear Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial... and other conditions

China, Australia
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Cervical Cancer | Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) | Metastatic Urothelial Carcinoma | Ovarian Cancer, Epithelial | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Triple Negative Breast Cancer (TNBC) | Malignant Pleural Mesothelioma... and other conditions

United States, United Kingdom
VM Oncology, LLC

Recruiting

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Sarcoma | Cervical Cancer | Breast Cancer | Adenoid Cystic Carcinoma | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Thymic Carcinoma | Lung Cancer | Mesothelioma | Bladder Cancer | Head and Neck Carcinoma | Uterine Cancer | Any Solid Tumors Progressed After a Prior Immunotherapy

United States, Puerto Rico
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2)

Cancer | Colorectal Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Lung Cancer | Rectal Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Colon Cancer | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | Pancreatic Neoplasm | Ovary Cancer | NSCLC, Recurrent | Non-Small Cell... and other conditions

United States
Western Sydney Local Health District
Bristol-Myers Squibb; University of Western Sydney

Recruiting

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity (ICEMELT)

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Gastric Cancer | Mesothelioma | Endometrial Cancer | Lung Cancer, Nonsmall Cell

Australia
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Active, not recruiting

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Bladder Urothelial Cancer | Endocervical...

United States
Constellation Pharmaceuticals

Recruiting

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Lymphoma, T-Cell | Mesothelioma, Malignant | Advanced Solid Tumor | Endometrial Cancer | Diffuse Large B Cell Lymphoma | Ovarian Clear Cell Carcinoma | Prostatic Neoplasms, Castration-Resistant

United States, Korea, Republic of, France, United Kingdom, Italy, Spain, Poland
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Active, not recruiting

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Glioblastoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Pancreatic Ductal Adenocarcinoma | Endocervical Cancer

United States, Korea, Republic of, Taiwan
Seagen Inc.

Recruiting

A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Colorectal Neoplasms | Pancreatic Neoplasms | Mesothelioma | Non-small Cell Lung Cancer | Cutaneous Melanoma

United States, Canada, Switzerland, France, Germany, United Kingdom

Clinical Trials on Mesothelioma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations